Sequencing Strategies After Progression in Multiple Myeloma

In this segment, Dr. Ajay Nooka engages the panel in a discussion on how to approach treatment sequencing for patients with relapsed and refractory multiple myeloma following disease progression. Dr. Noopur Raje and Dr. Surbhi Sidana share insights on how they evaluate available options, including novel agents and cell-based therapies, in the context of prior treatment exposure and disease trajectory. The panel discusses the importance of considering when to transition to a different therapeutic class versus continuing established regimens, emphasizing that this decision is influenced by factors such as response durability, disease aggressiveness, and patient-specific considerations. They also reflect on how emerging clinical data are shaping evolving sequencing strategies, particularly in earlier relapse settings. This segment highlights the complexity of treatment planning after progression and underscores the need for individualized approaches in managing multiple myeloma.